Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

Leukemia

Volumn 25, Issue 2, 2011, Pages 254-258

  Waanders, E ^a   Van Der Velden, V H J ^b   Van Der Schoot, C E ^c   Van Leeuwen, F N ^d   Van Reijmersdal, S V ^a   De Haas, V ^e   Veerman, A J ^e,f   Van Kessel, A G ^a   Hoogerbrugge, P M ^d,e   Kuiper, R P ^a   Van Dongen, J J M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ikaros; IKZF1; minimal residual disease (MRD); pediatric acute lymphoblastic leukemia (ALL); prognostic value; relapse prediction

Indexed keywords

IKAROS TRANSCRIPTION FACTOR; IKAROS ZINC FINGER 1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 79751538993     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.275     Document Type: Article

References (20)

1. Veerman AJ, Kamps WA, Van den Berg H, Van den Berg E, Bokkerink JP, Bruin MC et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
2. Dongen Van JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738. (Pubitemid 28534955)
3. Velden Van der VHJ, Corral L, Valsecchi MG, Jansen MW, De LP, Cazzaniga G et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
4. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, Velden Van der VHJ, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782. (Pubitemid 351552626)
5. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111: 5477-5485.
6. Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386-4393. (Pubitemid 34627205)
7. Velden Van der VHJ, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706-713. (Pubitemid 46444554)
8. Velden Van der VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611. (Pubitemid 46444541)
9. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
10. Kuiper RP, Waanders E, Van dV V, Van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
11. Dongen Van JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. (Pubitemid 38072572)
12. Szczepanski T, Van der Velden VHJ, Hoogeveen PG, de Bie M, Jacobs DC, Van Wering ER et al. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 2004; 103: 3798-3804. (Pubitemid 38596298)
13. Szczepanski T, Willemse MJ, Van Wering ER, Van Weerden JF, Kamps WA, Van Dongen JJ. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415-1423. (Pubitemid 32785311)
14. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435. (Pubitemid 30599324)
15. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118. (Pubitemid 29043725)
16. Bruggemann M, Van der Velden VHJ, Raff T, Droese J, Ritgen M, Pott C et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 709-719. (Pubitemid 38528651)
17. Velden Van der VHJ, Wijkhuijs JM, Jacobs DC, Van Wering ER, Van Dongen JJ. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372-1380.
18. Velden Van der VHJ, Willemse MJ, Van der Schoot CE, Hahlen K, Van Wering ER, Van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928-936. (Pubitemid 34537567)
19. Velden Van der VHJ, de Bie M, Van Wering ER, Van Dongen JJ. Immunoglobulin light chain gene rearrangements in precursor-Bacute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica 2006; 91: 679-682. (Pubitemid 43799469)
20. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-4162.